Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Celcuity Inc | CELC | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 16.94 | 04:17:20 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 16.94 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 8.389 - 22.188 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 16.94 | USD |
Celcuity Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 410M | 24.20M | - | 0 | -63.78M | -2.64 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Celcuity News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CELC Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 16.99 | 18.21 | 16.17 | 17.17 | 203,740 | -0.05 | -0.29% |
| 1 Month | 18.00 | 22.188 | 16.17 | 19.21 | 222,301 | -1.06 | -5.89% |
| 3 Months | 15.19 | 22.188 | 13.74 | 17.78 | 222,834 | 1.75 | 11.52% |
| 6 Months | 10.23 | 22.188 | 9.36 | 16.41 | 170,236 | 6.71 | 65.59% |
| 1 Year | 9.66 | 22.188 | 8.389 | 14.51 | 123,941 | 7.28 | 75.36% |
| 3 Years | 25.70 | 33.01 | 4.81 | 14.58 | 83,904 | -8.76 | -34.09% |
| 5 Years | 21.38 | 33.01 | 4.03 | 16.40 | 73,837 | -4.44 | -20.77% |
Celcuity Description
| Celcuity Inc is clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic (Rx) and companion diagnostic (CDx) strategy. The company's drug candidate, gedatolisib, is a potent, well-tolerated, small molecule dual inhibitor, administered intravenously, that selectively targets all class I isoforms of PI3K and mammalian target of rapamycin (mTOR). |
